Stay updated on MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Sign up to get notified when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.

Latest updates to the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe government funding lapse notice has been removed from the page, and this does not affect the study details or core content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedSubstantive study details (eligibility criteria, interventions, primary/secondary outcomes, and locations) appear unchanged. Minor formatting differences observed do not affect the content.SummaryDifference0.4%

- Check48 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference2%

- Check55 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes provided.SummaryDifference0.0%

- Check69 days agoChange DetectedUpdated the page revision to v3.0.2 from v3.0.1 and removed the 'Back to Top' element. No core content, pricing, or availability changes.SummaryDifference0.1%

- Check77 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

Stay in the know with updates to MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.